A new Chinese medicine drug X002 of Guizhou bailing Alzheimer's disease encountered obstacles in preclinical research
-
Last Update: 2020-04-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Guizhou bailing has a technical problem in the pre clinical research of class 1 Chinese medicine X002 The company is tackling the technical problem and cannot predict when it will be solved X002 is used to treat Alzheimer's disease It is a new drug in Guizhou bailing's prospectus together with the hepatitis B drug tifentai In March 2009, Guizhou bailing and Zunyi Medical College signed an agreement to jointly carry out the research and development of the drug, which is still in the pre clinical research and development stage.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
